Literature DB >> 17373915

Interaction between rifaximin and dietary fibre in patients with diverticular disease.

R D'Incà1, F Pomerri, M G Vettorato, E Dal Pont, V Di Leo, A Ferronato, V Medici, G C Sturniolo.   

Abstract

BACKGROUND: Cyclic administration of rifaximin in association with dietary fibre achieves symptomatic relief in uncomplicated diverticular disease (DD) by means of a still undefined mechanism. AIM: To investigate the effects of a combination of rifaximin and fibre on both hydrogen production by intestinal microflora and oro-anal transit time.
METHODS: In a controlled, double-blind crossover trial, 64 patients with uncomplicated DD were given bran (20 g/day) and randomly treated with rifaximin (1200 mg/day) or a placebo for 14 days. Evaluation was based on clinical status, breath test, oro-anal transit time and faecal weight.
RESULTS: The global symptomatic score was significantly reduced after rifaximin (7.1 +/- 4.1 to 4.1 +/- 3.3; P < 0.005) but not after placebo (6.8 +/- 3.8 to 6.1 +/- 3.5). Hydrogen production significantly increased after placebo from 198 +/- 134 to 267 +/- 161 ppm/min, while Rifaximin reduced it from 222 +/- 187 to 166 +/- 131 ppm/min (P = 0.05). The total oro-anal transit time decreased from 56.1 +/- 28.2 to 51.3 +/- 28.0 h in placebo and from 54.4 +/- 31.9 to 45.1 +/- 32.4 h (P < 0.05) in rifaximin-treated patients.
CONCLUSIONS: The administration of rifamixin improves the benefits of dietary fibre in uncomplicated DD by preventing its bacterial degradation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17373915     DOI: 10.1111/j.1365-2036.2007.03266.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  17 in total

1.  Diverticular disease: paradigm shifts in pathogenesis and treatment.

Authors:  Keta K Vaidya; Martin H Floch
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

2.  Italian consensus conference for colonic diverticulosis and diverticular disease.

Authors:  Rosario Cuomo; Giovanni Barbara; Fabio Pace; Vito Annese; Gabrio Bassotti; Gian Andrea Binda; Tino Casetti; Antonio Colecchia; Davide Festi; Roberto Fiocca; Andrea Laghi; Giovanni Maconi; Riccardo Nascimbeni; Carmelo Scarpignato; Vincenzo Villanacci; Bruno Annibale
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

3.  The medical and nonoperative treatment of diverticulitis.

Authors:  Heath Beckham; Charles B Whitlow
Journal:  Clin Colon Rectal Surg       Date:  2009-08

4.  Diverticular disease: A therapeutic overview.

Authors:  Antonio Tursi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-02-06

Review 5.  Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis.

Authors:  Gaurav Ghosh; Arun B Jesudian
Journal:  J Clin Exp Hepatol       Date:  2018-08-27

6.  Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies.

Authors:  Federico Sopeña; Angel Lanas
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

7.  Rifaximin: recent advances in gastroenterology and hepatology.

Authors:  Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

Review 8.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

9.  Breath Methane Levels Are Increased Among Patients with Diverticulosis.

Authors:  Cemal Yazici; Deniz Cagil Arslan; Rana Abraham; Kelly Cushing; Ali Keshavarzian; Ece A Mutlu
Journal:  Dig Dis Sci       Date:  2016-04-29       Impact factor: 3.199

10.  Colonic total and segmental transit times in healthy Italian adults.

Authors:  F Pomerri; G Dodi; M Nardin; P C Muzzio
Journal:  Radiol Med       Date:  2009-05-30       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.